Dr. Quan M. Bui
Cardiology (Cardiovascular Disease Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Colorado School of Medicine, Aurora (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 276
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: University of Colorado School of Medicine, Aurora
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
CA license A150740 (first issued 2017; current) -
Advanced Heart Failure and Transplant Cardiology Physician
CA license A150740 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 894
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 116 | 47 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 32 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 20 | 20 |
| Hospital discharge day management, more than 30 minutes | 18 | 18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in San Diego, CA | 89 |
| Metoprolol Succinate Other prescribers in San Diego, CA | 79 |
| Losartan Potassium Other prescribers in San Diego, CA | 71 |
| Jardiance (empagliflozin) Other prescribers in San Diego, CA | 57 |
| Eliquis (apixaban) Other prescribers in San Diego, CA | 46 |
| Entresto (sacubitril/valsartan) Other prescribers in San Diego, CA | 42 |
| Atorvastatin Calcium Other prescribers in San Diego, CA | 42 |
| Amlodipine Besylate Other prescribers in San Diego, CA | 41 |
| Bumetanide Other prescribers in San Diego, CA | 37 |
| Carvedilol Other prescribers in San Diego, CA | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 45 payments worth $12,826 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $5,677 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $3,079 |
| Baxter Healthcare | $2,205 |
| Abiomed | $888 |
| Kestra Medical Technology Services, Inc. | $369 |
| Novo Nordisk Inc | $282 |
| Philips North America LLC | $177 |
| UCB, Inc. | $125 |
| Consulting Fee | $9,506 |
|---|---|
| Food and Beverage | $2,465 |
| Travel and Lodging | $854 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Consulting Fee Kerendia · Cardio-Renal | $4,976 |
| E.r. Squibb & Sons, L.l.c. Dec 1, 2025 | Consulting Fee | $2,325 |
| Baxter Healthcare Apr 25, 2025 | Consulting Fee Fluid Systems - Infusion Systems; Fluid Systems - Research Devel · Fluid Systems | $2,205 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $300 |
| E.r. Squibb & Sons, L.l.c. Dec 2, 2025 | Travel and Lodging travel to NEW ORLEANS, LA | $263 |
| E.r. Squibb & Sons, L.l.c. Dec 2, 2025 | Travel and Lodging travel to NEW ORLEANS, LA | $191 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $45.00 |
| Bayer HealthCare Pharmaceuticals Inc. May 3, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $33.60 |
| Bayer HealthCare Pharmaceuticals Inc. May 2, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to San Diego, CA · in-kind | $21.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $96,247 in research payments for these studies, mostly to the institutions running them.
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, Inc. · Recruiting · NCT06563895 - A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.